421 related articles for article (PubMed ID: 27539748)
1. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.
Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F
Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780
[TBL] [Abstract][Full Text] [Related]
3. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
[TBL] [Abstract][Full Text] [Related]
5. Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss.
Nocera A; Tagliamacco A; Cioni M; Innocente A; Fontana I; Barbano G; Carrea A; Ramondetta M; Sementa A; Basso S; Quartuccio G; Klersy C; Bertocchi M; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
Am J Transplant; 2017 Mar; 17(3):692-702. PubMed ID: 27501275
[TBL] [Abstract][Full Text] [Related]
6. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.
Wiebe C; Gibson IW; Blydt-Hansen TD; Pochinco D; Birk PE; Ho J; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
Am J Transplant; 2015 Nov; 15(11):2921-30. PubMed ID: 26096305
[TBL] [Abstract][Full Text] [Related]
7. Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d⁺ Antibody-Mediated Rejection in Kidney Transplant Recipients.
Tatapudi VS; Kopchaliiska D; da Gente GJ; Buenaventura OF; Singh M; Laszik Z; Adey DB; Rajalingam R
Ann Transplant; 2021 Dec; 26():e934175. PubMed ID: 34848674
[TBL] [Abstract][Full Text] [Related]
8. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome.
Senev A; Coemans M; Lerut E; Van Sandt V; Daniëls L; Kuypers D; Sprangers B; Emonds MP; Naesens M
Am J Transplant; 2019 Mar; 19(3):763-780. PubMed ID: 30107078
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.
Bamoulid J; Roodenburg A; Staeck O; Wu K; Rudolph B; Brakemeier S; Halleck F; Lehner L; Schönemann C; Lachmann N; Budde K
Transplantation; 2017 Sep; 101(9):2165-2174. PubMed ID: 27653301
[TBL] [Abstract][Full Text] [Related]
10. Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.
Lachmann N; Niemann M; Reinke P; Budde K; Schmidt D; Halleck F; Pruß A; Schönemann C; Spierings E; Staeck O
Am J Transplant; 2017 Dec; 17(12):3076-3086. PubMed ID: 28613392
[TBL] [Abstract][Full Text] [Related]
11. Relationship among C1q-fixing de novo donor specific antibodies, C4d deposition and renal outcome in transplant glomerulopathy.
Messina M; Ariaudo C; Praticò Barbato L; Beltramo S; Mazzucco G; Amoroso A; Ranghino A; Cantaluppi V; Fop F; Segoloni GP; Biancone L
Transpl Immunol; 2015 Sep; 33(1):7-12. PubMed ID: 26160049
[TBL] [Abstract][Full Text] [Related]
12. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.
Luque S; Lúcia M; Melilli E; Lefaucheur C; Crespo M; Loupy A; Bernal-Casas D; Gomà M; Jarque M; Crespo E; Montero N; Manonelles A; Cruzado JM; Gil-Vernet S; Grinyó JM; Bestard O
Am J Transplant; 2019 Feb; 19(2):368-380. PubMed ID: 30085394
[TBL] [Abstract][Full Text] [Related]
13. Utility of protocol kidney biopsies for de novo donor-specific antibodies.
Parajuli S; Reville PK; Ellis TM; Djamali A; Mandelbrot DA
Am J Transplant; 2017 Dec; 17(12):3210-3218. PubMed ID: 28805293
[TBL] [Abstract][Full Text] [Related]
14. De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis.
Kiberd BA; Miller A; Martin S; Tennankore KK
Am J Transplant; 2016 Nov; 16(11):3212-3219. PubMed ID: 27106124
[TBL] [Abstract][Full Text] [Related]
15. Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter study.
Schinstock CA; Dadhania DM; Everly MJ; Smith B; Gandhi M; Farkash E; Sharma VK; Samaniego-Picota M; Stegall MD
Transpl Int; 2019 May; 32(5):502-515. PubMed ID: 30597643
[TBL] [Abstract][Full Text] [Related]
16. A Probabilistic Approach to Histologic Diagnosis of Antibody-Mediated Rejection in Kidney Transplant Biopsies.
Halloran PF; Famulski KS; Chang J
Am J Transplant; 2017 Jan; 17(1):129-139. PubMed ID: 27340822
[TBL] [Abstract][Full Text] [Related]
17. C1q-binding DSA and allograft outcomes in pediatric kidney transplant recipients.
Hayde N; Solomon S; Caglar E; Ge J; Qama E; Colovai A
Pediatr Transplant; 2021 Mar; 25(2):e13885. PubMed ID: 33131194
[TBL] [Abstract][Full Text] [Related]
18. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
Steggerda JA; Kim IK; Haas M; Zhang X; Kang A; Pizzo H; Kamil E; Jordan S; Puliyanda D
Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 29159992
[TBL] [Abstract][Full Text] [Related]
19. The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss.
Courant M; Visentin J; Linares G; Dubois V; Lepreux S; Guidicelli G; Thaunat O; Merville P; Couzi L; Taupin JL
Nephrol Dial Transplant; 2018 Oct; 33(10):1853-1863. PubMed ID: 29672702
[TBL] [Abstract][Full Text] [Related]
20. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
